Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
Covered in this story
What has happened since
- Kodiak Sciences Inc is up 165.2% since this was published, 27 days ago.
- Palo Alto Networks is down 5.3% since this was published, 27 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Kodiak Sciences Inc
- H.C. Wainwright: $99.9 → $126 by Oct 2027 · Buy via Investing.com
- H.C. Wainwright: $89.9 → $58 by Sep 2027 · Buy via Investing.com
- Jefferies: $89.9 → $112 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KOD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kodiak Sciences Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.